Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration

Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration

Item

http://www.wikidata.org/entity/Q24650864

Q24650864

about

Denosumab Patient-reported outcome instruments used to assess pain and functioning in studies of bisphosphonate treatment for bone metastases The reliability and validity of the Iranian version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for patients with Bone Metastases: the EORTC QLQ-BM22 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: A meta-analysis of randomized controlled trials.Improving management of patients with advanced cancer Quality of life measurement in bone metastases: A literature review.The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007.Breast cancer cells induce osteolytic bone lesions in vivo through a reduction in osteoblast activity in mice.Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw.Estimated number of prevalent cases of metastatic bone disease in the US adult population Letrozole in advanced breast cancer: the PO25 trial.The Prevention of Medication-related Osteonecrosis of the Jaw.Zoledronic acid inhibits aromatase activity and phosphorylation: potential mechanism for additive zoledronic acid and letrozole drug interaction The use of bisphosphonates in cancer patients.Significance and impact of bisphosphonate-induced acute phase responses.Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer Is community treatment best? a randomised trial comparing delivery of cancer treatment in the hospital, home and GP surgery.The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network.Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001-2009).Zoledronic acid use in cancer patients: more than just supportive care?Managing breakthrough pain.Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumors.Prescribing of zoledronic acid in a tertiary outpatient hospital setting.Adverse events across generations of bone-modifying agents in patients with solid tumor cancers reported in Phase III randomized trials.Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents.Treatment of distant metastases from follicular cell-derived thyroid cancer Patient-Reported Physical Function Measures in Cancer Clinical Trials.Feasibility of administering zoledronic acid in palliative patients being cared for in the community: results of a pilot study.Zoledronic acid in the management of metastatic bone disease Hepatitis C therapy at home: a hospital and home care partnership.Adult cancer pain.Treatment dynamics of bone-targeting agents among men with bone metastases from prostate cancer in the United States.Zoledronic acid increases the prevalence of medication-related osteonecrosis of the jaw in a dose dependent manner in rice rats (Oryzomys palustris) with localized periodontitis.Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid.Osteoclast inhibition impairs chondrosarcoma growth and bone destruction.Use of bone-modifying agents among breast cancer patients with bone metastasis: evidence from oncology practices in the US Farnesyl diphosphate synthase is important for the maintenance of glioblastoma stemness

P2860

Q24651938-45322946-AE0A-437D-9215-250AD01C8D95 Q26997330-8F14F7CA-AD42-4A30-AD92-5FE0219AB998 Q28303771-C0E58784-0872-43FE-BA4C-F57FAA73CA64 Q30367068-1B10206B-8785-41AB-9856-3430E25FBE16 Q33727640-2E79D857-E00E-4EDC-B1D2-D441B13BC630 Q34413634-8EBBEBEC-FB3F-4B44-8B9C-350A201DA27A Q34418172-A3D119E0-D128-4570-9EB9-2613C4DCBCA6 Q34561477-F987EE28-FE9A-45F8-AA37-7B97653587A6 Q34818002-3829ED56-AB3B-425B-8E88-A6984E4EFA95 Q34998432-E60EFA38-BFA4-4BD3-B1CD-BCD61446DFEE Q35584343-C1FCD57F-FC8B-44F4-B6C6-DF3455B7260F Q35938872-17006180-495E-46BF-BBC6-9DA9DFB4696C Q36026424-A0683960-65D8-4D29-88FE-DC225953B684 Q36292333-40629239-0D3A-4918-9388-FF4CE650581E Q36295928-0BE795F7-3A6C-4F91-B4C1-DC372FCAA8B4 Q36846894-558B2228-6C26-4BFC-9EE3-6C23FA52BFF7 Q37018333-732843CB-FAAB-43A7-819B-9FA0E1386533 Q37030106-47B04D69-9BC5-4518-AF7F-F2774A93A951 Q37182175-90D904E1-2661-4528-95D1-2A9580B51B0F Q37493951-41019F9A-6284-4542-98AE-341287A3FE8B Q37598932-6E216705-B6D5-4C41-B03E-488158675EE6 Q37827010-AAF74BDC-D7BB-4F5C-A2E2-1BB053926697 Q37828494-40669F89-6650-4118-9452-28A116E44DC1 Q37855651-FF3130EA-9A01-4F8E-B21A-BAC1A0F267E4 Q38040123-06709D0A-8551-4F7F-AB83-5FBC1C3E2D16 Q38041483-B6855714-D6A8-4A8D-9E34-6E162451FF72 Q38162877-ACDB8596-96E1-4E09-88D7-F967C532DB3D Q38297692-80AAA09C-8E7A-401E-995F-B434B5E07A7A Q38370352-EDF02DF0-15F9-409B-96A3-ADA24306EC85 Q39270037-CE268AA8-A802-405D-85AC-47160898A8A9 Q40020492-650A87EE-D950-4F7A-AAA0-F4309801F4D7 Q41687221-84EEF2CC-B70A-495D-8CCB-CBE0B990C16D Q43406527-D5BF343F-CBDD-47C8-9679-E32AFC37DBEC Q44426953-A5A60198-2FB4-4A04-8F7F-383D35118394 Q47189119-B813C0B0-8A8F-4B8B-814E-5AA5F6F82CD6 Q47559000-179061D6-BCE1-4C72-BE2D-28A14588AF94 Q47705480-8F2992A1-8E5C-407B-AD61-95AD5930B262 Q52652877-9DBC713F-2A0C-4975-8EDC-4D1A24B3498F Q57069083-8B4412EF-F70E-42AD-940E-8248F6EE135F Q58606161-2B5DC338-C527-4373-ADBC-2E0CB1EAEAF2

P2860

Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration

Item

http://www.wikidata.org/entity/Q24650864

description

2005 nî lūn-bûn

@nan

2005 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu